ESR2 and breast carcinoma: The authors also showed regulation of the breast cancer-relevant gene expression (RASSF1 in MCF-7 cells; IGFBP3, CTNNB1, and ERβ in LCC9 cells) with β-D-glucan at 10 and 50 μg/mL, indicating that this compound represents an attractive option for inhibiting endocrine-resistant breast cancer cell proliferation [51].